R.H. Bluestein & Co’s Charles River Laboratories CRL Stock Holding History

R.H. Bluestein & Co’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-899	Closed	-$255K	–	367
2022 Q1	$255K	Hold	899	–	–	0.01%	327
2021 Q4	$339K	Hold	899	–	–	0.01%	293
2021 Q3	$371K	Sell	899 -22	-2%	-$9.14K	0.01%	271
2021 Q2	$341K	Buy	921 +22	+2%	+$7.35K	0.01%	295
2021 Q1	$261K	Hold	899	–	–	0.01%	348
2020 Q4	$225K	Buy	+899	New	+$214K	0.01%	349

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

R.H. Bluestein & Co's CRL Position: Q2 2022 in Review

R.H. Bluestein & Co sold out of Charles River Laboratories (CRL) in Q2 2022, closing a stake of 899 shares — an estimated $255K sold.

R.H. Bluestein & Co first reported a position in CRL in Q4 2020 and held it in 6 quarters. The position peaked at $371K in Q3 2021. 628 funds tracked by Wall St. Rank hold CRL as of Q2 2022.

R.H. Bluestein & Co reported no remaining Charles River Laboratories position as of Q2 2022 after selling out during the quarter.
R.H. Bluestein & Co sold 899 Charles River Laboratories shares in Q2 2022, an estimated $255K.
R.H. Bluestein & Co first reported a position in Charles River Laboratories in Q4 2020 and held it in 6 quarters.
R.H. Bluestein & Co's Charles River Laboratories position peaked at $371K in Q3 2021.
628 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2022.

Based on R.H. Bluestein & Co's 13F filing for Q2 2022, filed 11 Aug 2022.